Journal of Gastrointestinal Cancer

, Volume 50, Issue 4, pp 879–887 | Cite as

Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience

  • Abdullah AlsuhaibaniEmail author
  • Ahmed Elashwah
  • Abdullah Alkafi
  • Camelia Constantinescus
  • Faisal ALzorkany
Original Research



We retrospectively evaluate local control rate at 6 months and 1 year in oligometastatic cancer patients treated with SBRT using CyberKnife.


Total of 21 patients with 24 treatment sites from February 2014 till June 2017 who were treated with SBRT in our institution were included in this study.


Eleven patients were males, 10 patients were females, median age at diagnosis was 63 years, and colorectal cancer is the most commonly diagnosed cancer in 18 patients. The abdomino-pelvic lymph nodes were the commonest treatment site in 11 (45.8%), average PTV volume of 46.4 cc. All the patients received SBRT with average (BED) of 97 GY, 7 treatment sites received BED of < 100GYgroup 1, and 17 received BED  100GY group 2. No reported G3 or G4 acute or chronic toxicity. The 6 months and 1 year local control (LC) were 95.8 and 88.2%, respectively. After a median follow-up of 16.8 months, 19(90.5%) patients were alive; among them, local progression was observed in 1 (4.1%) treatment site, while systemic progression in 4 (16.6%), and two (9.5%) patients died; they had both local and systemic failures. The 1-year local PFS rate was 82%. In univariate analysis, PTV volume was significantly correlated with LC rate at 6 months (p = 0.001), while the site of metastasis appeared to significantly correlate with PFS (p = 0.03).


SBRT using CyberKnife is feasible, safe, and effective treatment for oligometastatic sites. Six months and 1 year local control rate is 95.8 and 88.2% respectively in our patients cohort, treatment regimens with higher BED resulting in better 1-year local PFS, although it was not statistically significant. A larger cohort of patients and longer follow up is required for better evaluation.


Oligometastatic Cancer Radiation Sterotactic SBRT CyberKnife Metastatic disease Local control 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.CrossRefGoogle Scholar
  2. 2.
    Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the “international registry of lung metastases.”. J Thorac Oncol. 2011;6(8):1373–8.CrossRefGoogle Scholar
  3. 3.
    Simmonds PC, Primrose JN. Colquitt JL, et al.Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–99.CrossRefGoogle Scholar
  4. 4.
    Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118(11):2962–70.CrossRefGoogle Scholar
  5. 5.
    Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112(3):650–8.CrossRefGoogle Scholar
  6. 6.
    Ahmed KA, Stauder MC, Miller RC, Bauer HJ, Rose PS, Olivier KR, et al. Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):e803–9.CrossRefGoogle Scholar
  7. 7.
    Shaw E, Scott C, Souhami L, Dinapoli R, Bahary JP, Kline R, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). Int J Radiat Oncol Biol Phys. 1996;34(3):647–54.CrossRefGoogle Scholar
  8. 8.
    Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47(2):291–8.CrossRefGoogle Scholar
  9. 9.
    Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD. Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys. 2006;64(3):898–903.CrossRefGoogle Scholar
  10. 10.
    Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76(2):326–32.CrossRefGoogle Scholar
  11. 11.
    Heinzerling JH, Anderson JF, Papiez L, Boike T, Chien S, Zhang G, et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys. 2008;70(5):1571–8.CrossRefGoogle Scholar
  12. 12.
    Chen J, Morin O, Aubin M, Bucci MK, Chuang CF, Pouliot J. Dose-guided radiation therapy with megavoltage cone-beam CT. Br J Radiol. 2006;79(1):S87–98.CrossRefGoogle Scholar
  13. 13.
    Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83(991):554–68.CrossRefGoogle Scholar
  14. 14.
    Timmerman R, Paulus R, Galvin J,et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. 2010 17;303(11):1070–6. doi: CrossRefGoogle Scholar
  15. 15.
    Bilal H, Mahmood S, Rajashanker B,et al. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?. 2012 Aug;15(2):258–65. doi: Epub 2012 May 10.CrossRefGoogle Scholar
  16. 16.
    Gewanter RM, Rosenzweig KE, Chang JY,et al. ACR appropriateness criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. 2010;34(3):228-49. doi: Scholar
  17. 17.
    Kamran A. Ahmed, MD and Javier al. Stereotactic body radiotherapy in the management of oligometastatic disease. Cancer Control January 2016, Vol. 23, No. 1.Google Scholar
  18. 18.
    Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18:215–22.CrossRefGoogle Scholar
  19. 19.
    Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving 30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int. J. Radiat. Oncol., Biol., Phys. 2009;76:796–801.CrossRefGoogle Scholar
  20. 20.
    Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–8.CrossRefGoogle Scholar
  21. 21.
    Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19(1):164–70.CrossRefGoogle Scholar
  22. 22.
    Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012;75(1):77–81.CrossRefGoogle Scholar
  23. 23.
    Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27(10):1579–84.CrossRefGoogle Scholar
  24. 24.
    Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60(1):186–96.CrossRefGoogle Scholar
  25. 25.
    Fumagalli I, Bibault JE, Dewas S, Kramar A, Mirabel X, Prevost B, et al. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol. 2012;7:164.CrossRefGoogle Scholar
  26. 26.
    McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73(1):112–8.CrossRefGoogle Scholar
  27. 27.
    Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011;101(2):255–9.CrossRefGoogle Scholar
  28. 28.
    Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012;75(1):77–81.CrossRefGoogle Scholar
  29. 29.
    Ahmed KA, Berglund AE, Hoffe SE, et al. Differences between colon cancer primaries and metastases utilizing a molecular assay for tumor radiosensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys. 2015;92(4):837–42.CrossRefGoogle Scholar
  30. 30.
    Rainer J. Klement radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases. Radiother Oncol. 2017;123:218–26.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Oncology CenterUniversity Medical City, King Saud UniversityRiyadhSaudi Arabia
  2. 2.Radiation oncology department King Faisal specialized hospital and research centerRiyadhSaudi Arabia
  3. 3.Kasr Aleini center of clinical oncology and nuclear medicine (NEMROCK)Cairo UniversityCairoEgypt

Personalised recommendations